Leukemia Myelomonocytic Chronic
📧 Sign up to get email alerts when something new happens for Leukemia Myelomonocytic Chronic.
Sign up freeTop drugs studied for this disease
-
EMA approval · 2026-06-12EMA Authorised: Azacitidine Mylan (azacitidine) — Mylan Pharmaceuticals Limited
European Medicines Agency authorises Azacitidine Mylan for myelodysplastic syndromes and various leukemias, confirming market authorization …
-
EMA approval · 2024-01-10EMA Authorised: Azacitidine betapharm (azacitidine) — betapharm Arzneimittel GmbH
Azacitidine betapharm (azacitidine) has been authorised in the EU for use in myelodysplastic syndromes and various leukemias, with betapharm…
-
EMA withdrawal · 2021-08-04EMA Withdrawn: Azacitidine Celgene (azacitidine) — Celgene Europe BV
The EMA has withdrawn the azacitidine product Celgene Europe BV from the market.
-
CLINICAL_TRIALS trial_result · 2020-09-23Clinical Trial Update: An Efficacy and Safety Study of Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine in Participants With Higher-Risk Myelodysplastic Syndromes (HR MDS), Chronic Myelomonocytic Leukemia (CMML) and Low-Blast Acute Myelogenous Leukemia (AML) [Phase 2]
Phase 2 trial evaluating pevonedistat plus azacitidine versus azacitidine alone in higher-risk myelodysplastic syndromes, chronic myelomonoc…